A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 378 participants.
Also called NCT07680829
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 378 participants
- Registry
-
NCT07680829
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07680829. Randomized; quadruple masking; primary purpose treatment. Start 2026-08 (anticipated); primary completion 2030-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- DR10624 Subcutaneous Injection
- Intervention (Drug)
- Icosapent Ethyl Oral Capsule
- Intervention (Drug)
- Matching Placebo Subcutaneous Injection
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.
Record details
- Record id
cardio:ct-nct07680829- Content hash
2c309794d06424a589cbde0e0690119c69aeea627f3acb3b4b28c8f2cc8400ab